Clinical efficacy of treatment for subclinical-stage axial diabetic optic neuropathy
Journal Title: Офтальмологический журнал - Year 2018, Vol 0, Issue 4
Abstract
Background: There is no standard of therapy for the treatment of diabetic optic neuropathy (DON). Purpose: To assess the clinical efficacy of thioctic acid, topical brimonidine tartrate and a combination of vitamins В1, В6, and В12 in the management of subclinical-stage axial DON. Materials and Methods: Forty patients (63 eyes) were followed up after being diagnosed with subclinical-stage axial DON. The adjunct group was composed of 20 patients (32 eyes) who were administered (1) thioctic acid (Berlithion) at a dose of one 300 mg tablet a day for 42 days, (2) a 2 ml intramuscular injection of Milgamma, once per 3 days for 21 days, followed by switching to oral regimen, 1 tablet per 3 days for 21 days in two courses during a year, and (3) topical brimonidine tartrate 0.2%, 1-2 drops twice a day on a constant basis, as adjunctive to hypoglycemic therapy. The control group (20 patients; 31 eyes) received hypoglycemic therapy only. In addition to routine eye examination, retinal and optic nerve optical coherence tomography and electrophysiology were performed. Patients underwent an examination at baseline, 1.5 months, 6 months, 7.5 months, 13.5 months, 24 months and 25.5 months after treatment. Results: No progression of optic nerve damage was found in all 32 affected eyes of the adjunct group versus no progression, progression to mild-stage axial DON, and progression to advanced-stage axial DON in 64.5% (20 eyes), 35.5% (11 eyes) and 6.5% (2 eyes), respectively, of the controls at the 25.5-month time point. We found that our treatment attenuated the progression of optic nerve damage in subclinical-stage axial DON, with 25.9% better visual acuity, 29.5 % lower electrically evoked phosphene thresholds, 69.3% less ganglion cell complex (GCC) focal loss volume (FLV), and 29.8% less thickness of the cribriform plate compared to controls at 25.5 months. Conclusion: Our treatment was found to be clinically efficacious in attenuating the progression of optic nerve damage in subclinical-stage axial DON.
Authors and Affiliations
M. Karliychuk, P. Bezditko
Keywords
Related Articles
- EP ID EP423684
- DOI 10.31288/oftalmolzh201843236
- Views 101
- Downloads 0
Comparison study of results of vitrectomy and vitrectomy with scleral buckling for the treatment of patients with rhegmatogenous retinal detachment at high risk proliferative vitreoretinopathy
The aim of our study was to analyze the effectiveness of vitrectomy and vitrectomy with scleral buckling in patients with a high risk of proliferative vitreoretinopathy. Material and Methods: Of the 367 patients (394 ey...
Relationship between severity of HIV infection and ocular pathology in patients with pulmonary tuberculosis
Background: Pulmonary tuberculosis most commonly develops and often becomes generalized among HIV-infected patients. HIV-positive individuals present extra-pulmonary forms of tuberculosis twice as often as HIV-negative i...
Results of vitreous surgery with 20% C3F8/air mixture for macular holes larger than 800 μm
Background: Vitreous surgery for large macular holes is still a challenge to the ophthalmologist. Purpose: To assess the efficacy of the 20% C3F8/air mixture in the vitrectomy surgery for macular holes > 800 μm in diame...
The level of pediatric cataract in regions according to data of Ministry of Health of Ukraine for 2007-2016 years
The purpose of this study was to examine the changes in incidence and prevalence of cataract during the 10-year period between 2007-2016 among children who had been registered in the Health Care of Ukraine. In Ukraine, t...
A new set of tables for detecting thresholds of color sensitivity in children with acquired myopia
Background. Color vision, like visual acuity, is a function of cone cells in the retina of the eye. Development and improvement of this function goes in parallel with central vision development. The main cause of impaire...